Complaint and Demand for Jury Trial Against ELI Lilly and Company, Lilly USA, LLC, Novo Nordisk A/S, Novo Nordisk INC. , Filed by Chiffon M. Williams. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(Drago, Jon)

Document #1 Filed 03/30/2026 · 11 pages · District Court, E.D. Pennsylvania · View original PDF

1Full (first, middle, and last) name of Plaintiff injured/deceased due to use of GLP- 1 RA Product(s): ______________________________________________________________.

2If applicable, full name(s) and representative capacity of Plaintiff(s) alleging wrongful death claim: ___________________________________________________________, as ___________________________ of the estate of ___________________________, deceased.

3If applicable, full name(s) of Plaintiff(s) alleging survival claims, as permitted under state law(s): ______________________________________________________________.

4If applicable, full name(s) of Plaintiff(s) alleging loss of consortium or loss of services: ______________________________________________________________________. Defendant(s)

5Plaintiff(s)/Decedent’s Representative is/are suing the following Defendant(s) (check all that apply):

_____ Novo Nordisk Inc. _____ Novo Nordisk A/S _____ Eli Lilly and Company _____ Lilly USA, LLC _____ other(s) (identify): ___________________________________________

Chiffon M. Williams ✔ ✔ ✔ ✔ JURISDICTION AND VENUE

6City and state of Plaintiff(s)’ current residence (or in a case brought on behalf of a Decedent, Decedent’s last permanent residence):

7State where Plaintiff/Decedent was prescribed the GLP-1RA Product(s) at issue:

8State of Plaintiff’s/Decedent’s residence at time of their use of the GLP-1RA Product(s) at issue:

9City and state of Plaintiff(s)’/Decedent’s residence at time of diagnosis of injury:

10Jurisdiction is based on: _____ diversity of citizenship pursuant to 28 U.S.C. § 1332 _____ other (plead in sufficient detail as required by applicable rules):

11The District Court(s) where Plaintiff(s) might have otherwise filed this Short Form Complaint, absent this Court’s CMO No. 14, and/or to where remand could be ordered:

12Venue is proper in the District Court identified in Paragraph 11 because: _____ a substantial part of the events and omissions giving rise to Plaintiff(s)’

claims occurred there

Chicago, Illinois Illinois Illinois Chicago, Illinois Northern District of Illinois ✔

✔

_____ other (plead in sufficient detail as required by applicable rules):

13If applicable, identify the citizenship of any additional Defendant(s) named above:

PRODUCT USE

14Plaintiff/Decedent used the following GLP-1 RA Product(s) for which claims are being asserted in this case (check all that apply):

_____ Ozempic (semaglutide) _____ Wegovy (semaglutide) _____ Rybelsus (oral semaglutide) _____ Victoza (liraglutide) _____ Saxenda (liraglutide) _____ Trulicity (dulaglutide) _____ Mounjaro (tirzepatide) _____ Zepbound (tirzepatide) _____ Other(s) (specify): ____________________________________________

15To the best of Plaintiff(s)’ knowledge, Plaintiff/Decedent used GLP-1 RA Product(s) during the following approximate date range(s) (month(s) and year(s)) (if multiple products, specify date range(s) for each product):

Approx. May 2023 - July 2024 (Ozempic) Approx. March 2024 - April 2024 (Trulicity)

✔

Read the full filing

You’re reading pages 1–5 of 11. Register free to read the complete 11-page transcript on this page.

These are public U.S. federal court records, available free from PACER and the court. Registration unlocks our full on-page transcript — a convenience service.

Public U.S. federal court record (district court docket 73112596, document 1). Source via the RECAP Archive (Free Law Project). The same record is available from PACER. Informational only — not legal advice.